Shares of Merck (NYSE:MRK) traded marginally higher on Friday after falling from a high of $119.38 from the past seven ...

Merck & Co.’s said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet ...

Merck said on Wednesday its therapy did not meet the main goal of a late-stage trial evaluating it in patients with a type of ...

We recently compiled a list of the 10 Undervalued Wide Moat Stocks to Buy According to Analysts. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the ...

Shares of Merck & Co. Inc. MRK slipped 1.43% to $113.09 Thursday, on what proved to be an all-around favorable trading ...

Evaxion Biotech enters an expanded collaboration with Merck, granting an option to license preclinical vaccine candidates.

Merck (MRK) stock is in focus as a Phase 3 trial for its cancer drug Keytruda in colorectal cancer patients did not meet ...

When we invest, we're generally looking for stocks that outperform the market average. Buying under-rated businesses ...

Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on Evaxion Biotech (EVAX – Research Report). The ...

圣安生医(6926)以创新HLA-G标靶外泌体药物递送平台(SOB100)系列药物的研发，荣获第11届默克(Merck)特别奖。默克全球新兴生物科技资助项目于2014年启动，虽然每年提供全球不同区域的生技公司申请，这是继2019年第一次 ...

Merck & Co Inc. (MRK) on Wednesday said its Phase 3 KEYFORM-007 study evaluating the company's drug candidate favezelimab in ...

上周末，生物技术公司Summit ...